{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T16:28:13Z","timestamp":1794414493631,"version":"4.9.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"16","license":[{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1038\/s41433-026-04904-4","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T06:17:31Z","timestamp":1790230651000},"page":"2516-2525","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Potential protective associations of antidiabetic and lipid-lowering therapies with retinal vein occlusion risk: a systematic review and meta-analysis"],"prefix":"10.1038","volume":"40","author":[{"given":"Anas","family":"Alamoudi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Alnabihi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2301-2218","authenticated-orcid":false,"given":"Sultan","family":"Al-Qahtani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"},{"role":"corresponding-author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4596-735X","authenticated-orcid":false,"given":"Waleed K.","family":"Alsarhani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter J.","family":"Kertes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,9,24]]},"reference":[{"key":"4904_CR1","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1038\/eye.2011.92","volume":"25","author":"M Laouri","year":"2011","unstructured":"Laouri M, Chen E, Looman M, Gallagher M. The burden of disease of retinal vein occlusion: review of the literature. Eye (Lond). 2011;25:981\u20138. https:\/\/doi.org\/10.1038\/eye.2011.92.","journal-title":"Eye (Lond)"},{"key":"4904_CR2","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1111\/j.1538-7836.2010.03909.x","volume":"8","author":"M Rehak","year":"2010","unstructured":"Rehak M, Wiedemann P. Retinal vein thrombosis: pathogenesis and management. J Thrombosis Haemost. 2010;8:1886\u201394. https:\/\/doi.org\/10.1111\/j.1538-7836.2010.03909.x.","journal-title":"J Thrombosis Haemost"},{"key":"4904_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2014\/724780","volume":"2014","author":"P Kolar","year":"2014","unstructured":"Kolar P. Risk factors for central and branch retinal vein occlusion: a meta-analysis of published clinical data. J Ophthalmol. 2014;2014:1\u20135. https:\/\/doi.org\/10.1155\/2014\/724780.","journal-title":"J Ophthalmol"},{"key":"4904_CR4","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.survophthal.2024.06.007","volume":"69","author":"E Hashemi","year":"2024","unstructured":"Hashemi E, Looha MA, Mazaherinia H, Samadaeian N, Panahi NM, Bonilla-Escobar FJ, et al. Risk of stroke development following retinal vein occlusion: a systematic review and meta-analysis. Surv Ophthalmol. 2024;69:924\u201336. https:\/\/doi.org\/10.1016\/j.survophthal.2024.06.007.","journal-title":"Surv Ophthalmol"},{"key":"4904_CR5","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s40942-024-00606-9","volume":"10","author":"KY Chen","year":"2024","unstructured":"Chen KY, Chan HC, Chan CM. Is retinal vein occlusion highly associated with an increased risk of myocardial infarction? A systematic review and meta-analysis. Int J Retin Vitr. 2024;10:86 https:\/\/doi.org\/10.1186\/s40942-024-00606-9.","journal-title":"Int J Retin Vitr"},{"key":"4904_CR6","doi-asserted-by":"publisher","DOI":"10.1177\/14791641241271899","volume":"21","author":"Y Yao","year":"2024","unstructured":"Yao Y, Wang Q, Yang J, Yan Y, Wei W. Prevalence and risk factors of retinal vein occlusion in individuals with diabetes: the kailuan eye study. Diab Vasc Dis Res. 2024;21:14791641241271899. https:\/\/doi.org\/10.1177\/14791641241271899.","journal-title":"Diab Vasc Dis Res"},{"key":"4904_CR7","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1016\/j.jacc.2020.02.056","volume":"75","author":"T Wilcox","year":"2020","unstructured":"Wilcox T, De Block C, Schwartzbard AZ, Newman JD. Diabetic agents, from metformin to SGLT2 inhibitors and GLP1 receptor agonists: JACC focus seminar. J Am Coll Cardiol. 2020;75:1956\u201374. https:\/\/doi.org\/10.1016\/j.jacc.2020.02.056.","journal-title":"J Am Coll Cardiol"},{"key":"4904_CR8","doi-asserted-by":"publisher","first-page":"387","DOI":"10.3390\/cells14050387","volume":"14","author":"M Gaggini","year":"2025","unstructured":"Gaggini M, Sabatino L, Suman AF, Chatzianagnostou K, Vassalle C. Insights into the roles of GLP-1, DPP-4, and SGLT2 at the crossroads of cardiovascular, renal, and metabolic pathophysiology. Cells. 2025;14:387 https:\/\/doi.org\/10.3390\/cells14050387.","journal-title":"Cells"},{"key":"4904_CR9","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1136\/bjophthalmol-2021-319232","volume":"107","author":"J Sterling","year":"2023","unstructured":"Sterling J, Hua P, Dunaief JL, Cui QN, VanderBeek BL. Glucagon-like peptide 1 receptor agonist use is associated with reduced risk for glaucoma. Br J Ophthalmol. 2023;107:215\u201320. https:\/\/doi.org\/10.1136\/bjophthalmol-2021-319232.","journal-title":"Br J Ophthalmol"},{"key":"4904_CR10","doi-asserted-by":"publisher","unstructured":"Messak M, Abdelmageed A, Senbel AA, Khattab YA, Mandour Y, Shaker O, et al. Efficacy and safety of GLP-1 agonists in Parkinson\u2019s disease: a systematic review and meta-analysis of randomized controlled trials. Naunyn-Schmiedeberg\u2019s Arch Pharmacol. 2025. https:\/\/doi.org\/10.1007\/s00210-025-03932-3","DOI":"10.1007\/s00210-025-03932-3"},{"key":"4904_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.907340","volume":"13","author":"B Zhou","year":"2022","unstructured":"Zhou B, Shi Y, Fu R, Ni H, Gu L, Si Y, et al. Relationship between SGLT-2i and ocular diseases in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. Front Endocrinol (Lausanne). 2022;13:907340. https:\/\/doi.org\/10.3389\/fendo.2022.907340.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"4904_CR12","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.jacl.2022.07.004","volume":"16","author":"W Masson","year":"2022","unstructured":"Masson W, Corral P, Barbagelata L, Lavalle-Cobo A, Nogueira JP, Siniawski D, et al. Reduction of cardiovascular events with the use of lipid-lowering medication in patients with familial hypercholesterolemia or severe primary hypercholesterolemia: A systematic review. J Clin Lipidol. 2022;16:562\u201373. https:\/\/doi.org\/10.1016\/j.jacl.2022.07.004.","journal-title":"J Clin Lipidol"},{"key":"4904_CR13","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1136\/bjophthalmol-2021-318789","volume":"107","author":"Y Yuan","year":"2023","unstructured":"Yuan Y, Wang W, Shang X, Xiong R, Ha J, Zhang L, et al. Association between statin use and the risks of glaucoma in Australia: a 10-year cohort study. Br J Ophthalmol. 2023;107:66\u201371. https:\/\/doi.org\/10.1136\/bjophthalmol-2021-318789.","journal-title":"Br J Ophthalmol"},{"key":"4904_CR14","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1038\/s41433-018-0066-7","volume":"32","author":"A Al-Janabi","year":"2018","unstructured":"Al-Janabi A, Lightman S, Tomkins-Netzer O. Statins in retinal disease. Eye (Lond). 2018;32:981\u201391. https:\/\/doi.org\/10.1038\/s41433-018-0066-7.","journal-title":"Eye (Lond)"},{"key":"4904_CR15","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.004180","volume":"6","author":"S Yu","year":"2017","unstructured":"Yu S, Chu Y, Li G, Ren L, Zhang Q, Wu L. Statin use and the risk of cataracts: a systematic review and meta-analysis. J Am Heart Assoc. 2017;6:e004180. https:\/\/doi.org\/10.1161\/JAHA.116.004180.","journal-title":"J Am Heart Assoc"},{"key":"4904_CR16","doi-asserted-by":"publisher","DOI":"10.7189\/jogh.09.010427","volume":"9","author":"P Song","year":"2019","unstructured":"Song P, Xu Y, Zha M, Zhang Y, Rudan I. Global epidemiology of retinal vein occlusion: a systematic review and meta-analysis of prevalence, incidence, and risk factors. J Glob Health. 2019;9:010427. https:\/\/doi.org\/10.7189\/jogh.09.010427.","journal-title":"J Glob Health"},{"key":"4904_CR17","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.jtha.2022.10.003","volume":"21","author":"E Valeriani","year":"2023","unstructured":"Valeriani E, Paciullo F, Porfidia A, Pignatelli P, Candeloro M, Di Nisio M, et al. Antithrombotic treatment for retinal vein occlusion: a systematic review and meta-analysis. J Thrombosis Haemost. 2023;21:284\u201393. https:\/\/doi.org\/10.1016\/j.jtha.2022.10.003.","journal-title":"J Thrombosis Haemost"},{"key":"4904_CR18","unstructured":"Higgins J, Thomas J, Chandler J, Cumpston M, LI T, Page M, et al. Cochrane Handbook for Systematic Reviews of Interventions (updated August 2023).version 6.4. Avaliable www.training.cochrane.org\/handbook [Internet]. 2023. Available from: www.training.cochrane.org\/handbook"},{"key":"4904_CR19","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71 https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"key":"4904_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan\u2014a web and mobile app for systematic reviews. Syst Rev. 2016;5:210. https:\/\/doi.org\/10.1186\/s13643-016-0384-4.","journal-title":"Syst Rev"},{"key":"4904_CR21","unstructured":"Wells G, Shea B, O\u2019Connel D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyse [Internet]. 2012 [cited 2024 Aug 16]. Available from: https:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp"},{"key":"4904_CR22","unstructured":"Viswanathan M, Ansari MT, Berkman ND, Chang S, Hartling L, McPheeters M, et al. Assessing the Risk of Bias of Individual Studies in Systematic Reviews of Health Care Interventions. In: Methods Guide for Effectiveness and Comparative Effectiveness Reviews [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2008 [cited 2024 Aug 16]. (AHRQ Methods for Effective Health Care). Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK91433\/."},{"key":"4904_CR23","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jclinepi.2019.12.023","volume":"121","author":"F Foroutan","year":"2020","unstructured":"Foroutan F, Guyatt G, Zuk V, Vandvik PO, Alba AC, Mustafa R, et al. GRADE guidelines 28: use of GRADE for the assessment of evidence about prognostic factors: rating certainty in identification of groups of patients with different absolute risks. J Clin Epidemiol. 2020;121:62\u201370. https:\/\/doi.org\/10.1016\/j.jclinepi.2019.12.023.","journal-title":"J Clin Epidemiol"},{"key":"4904_CR24","doi-asserted-by":"publisher","unstructured":"Zhang Y, Akl EA, Sch\u00fcnemann HJ Using systematic reviews in guideline development: the GRADE approach. Res Synth Methods. 2018 Jul 14. https:\/\/doi.org\/10.1002\/jrsm.1313.","DOI":"10.1002\/jrsm.1313"},{"key":"4904_CR25","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1111\/biom.13197","volume":"76","author":"TJ VanderWeele","year":"2020","unstructured":"VanderWeele TJ. Optimal approximate conversions of odds ratios and hazard ratios to risk ratios. Biometrics. 2020;76:746\u201352. https:\/\/doi.org\/10.1111\/biom.13197.","journal-title":"Biometrics"},{"key":"4904_CR26","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629\u201334. https:\/\/doi.org\/10.1136\/bmj.315.7109.629.","journal-title":"BMJ"},{"key":"4904_CR27","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1167\/iovs.65.6.19","volume":"65","author":"HR Tsai","year":"2024","unstructured":"Tsai HR, Lin YJ, Yeh JI, Lin SM, Liu PPS, Chang YC, et al. Use of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes and the incidence of retinal vein occlusion in Taiwan. Invest Ophthalmol Vis Sci. 2024;65:19 https:\/\/doi.org\/10.1167\/iovs.65.6.19.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"4904_CR28","doi-asserted-by":"publisher","first-page":"9864","DOI":"10.3390\/ijerph18189864","volume":"18","author":"CC Chien","year":"2021","unstructured":"Chien CC, Chen PH, Chung CH, Sun CA, Chien WC, Chien KH. Association between statins and retinal vascular occlusion: a population-based cohort study. IJERPH. 2021;18:9864 https:\/\/doi.org\/10.3390\/ijerph18189864.","journal-title":"IJERPH"},{"key":"4904_CR29","doi-asserted-by":"publisher","DOI":"10.1177\/25158414211063076","volume":"14","author":"K Simmons","year":"2022","unstructured":"Simmons K, Singh P, Borkar DS, Birnbaum F, Thomas AS, Fekrat S. The effect of select systemic medications on outcomes in diabetics with central retinal vein occlusion. Ophthalmol Eye Dis. 2022;14:25158414211063076. https:\/\/doi.org\/10.1177\/25158414211063076.","journal-title":"Ophthalmol Eye Dis"},{"key":"4904_CR30","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.arteri.2020.07.001","volume":"33","author":"JJ Napal Lecumberri","year":"2021","unstructured":"Napal Lecumberri JJ, Gonz\u00e1lez Bores P, Cuesta Mar\u00edn A, Caballero Avenda\u00f1o FA, Olmos Mart\u00ednez JM, Hern\u00e1ndez Hern\u00e1ndez JL. Perfil lip\u00eddico y concentraciones s\u00e9ricas de \u00e1cido f\u00f3lico, vitamina B12 y homociste\u00edna en pacientes con obstrucci\u00f3n venosa retiniana. Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis. 2021;33:169\u201374. https:\/\/doi.org\/10.1016\/j.arteri.2020.07.001.","journal-title":"Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis"},{"key":"4904_CR31","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1097\/IAE.0000000000004426","volume":"45","author":"F Thomas","year":"2025","unstructured":"Thomas F, Lochhead J. Serotonin reuptake inhibitors may reduce the risk of retinal vein occlusion. Retina. 2025;45:1160\u20137. https:\/\/doi.org\/10.1097\/IAE.0000000000004426.","journal-title":"Retina"},{"key":"4904_CR32","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s00417-016-3569-6","volume":"255","author":"VM Matei","year":"2017","unstructured":"Matei VM, Xia JY, Nguyen C. Poor outcomes despite aspirin or statin use in high-risk patients with retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2017;255:761\u20136. https:\/\/doi.org\/10.1007\/s00417-016-3569-6.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"4904_CR33","doi-asserted-by":"publisher","first-page":"e2023035","DOI":"10.4178\/epih.e2023035","volume":"45","author":"J Yoo","year":"2023","unstructured":"Yoo J, Shin JY, Jeon J, Kim J. Impact of statin treatment on cardiovascular events in patients with retinal vein occlusion: a nested case-control study in Korea. Epidemiol Health. 2023;45:e2023035 https:\/\/doi.org\/10.4178\/epih.e2023035.","journal-title":"Epidemiol Health"},{"key":"4904_CR34","doi-asserted-by":"publisher","unstructured":"Lin TC, Hwang DK, Hsu CC, Peng CH, Wang ML, Chiou SH, et al. Protective effect of metformin against retinal vein occlusions in diabetes mellitus \u2013 A nationwide population-based study. Vavvas DG, editor. PLoS ONE. 2017;12:e0188136. https:\/\/doi.org\/10.1371\/journal.pone.0188136","DOI":"10.1371\/journal.pone.0188136"},{"key":"4904_CR35","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.2337\/dc20-3133","volume":"44","author":"MK Lee","year":"2021","unstructured":"Lee MK, Kim B, Han K, Lee JH, Kim M, Kim MK, et al. Sodium\u2013glucose cotransporter 2 inhibitors and risk of retinal vein occlusion among patients with type 2 diabetes: a propensity score\u2013matched cohort study. Diab Care. 2021;44:2419\u201326. https:\/\/doi.org\/10.2337\/dc20-3133.","journal-title":"Diab Care"},{"key":"4904_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2025.100734","volume":"5","author":"SY Pan","year":"2025","unstructured":"Pan SY, Weng CH, Tsai SF, Sheen YJ, Lin HJ, Tien PT, et al. Risk of retinal vein occlusion between glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Ophthalmol Sci. 2025;5:100734. https:\/\/doi.org\/10.1016\/j.xops.2025.100734.","journal-title":"Ophthalmol Sci"},{"key":"4904_CR37","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.cca.2007.03.024","volume":"382","author":"T Stojakovic","year":"2007","unstructured":"Stojakovic T, Scharnagl H, M\u00e4rz W, Winkelmann BR, Boehm BO, Schmut O. Low density lipoprotein triglycerides and lipoprotein(a) are risk factors for retinal vascular occlusion. Clin Chim Acta. 2007;382:77\u201381. https:\/\/doi.org\/10.1016\/j.cca.2007.03.024.","journal-title":"Clin Chim Acta"},{"key":"4904_CR38","doi-asserted-by":"publisher","unstructured":"Yuan W, Xu X, Zhang X, Fan W, Zhou W, Zhao F. Exploring the associations of obesity and glycemic traits with retinal vein occlusion: a univariate and multivariable mendelian randomization study. Ophthalmic Epidemiol. 2025;1\u20139. https:\/\/doi.org\/10.1080\/09286586.2025.2458245","DOI":"10.1080\/09286586.2025.2458245"},{"key":"4904_CR39","doi-asserted-by":"publisher","DOI":"10.1111\/cns.14888","volume":"30","author":"A Mady","year":"2024","unstructured":"Mady A, Nabil Y, Daoud A, Alnajjar AZ, Alsalloum T, Marwan M, et al. Determining the role of statins in Parkinson\u2019s disease risk reduction and disease modification: a comprehensive meta-analysis of 4 million participants\u2019 data. CNS Neurosci Ther. 2024;30:e14888. https:\/\/doi.org\/10.1111\/cns.14888.","journal-title":"CNS Neurosci Ther"},{"key":"4904_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-025-01957-w","volume":"26","author":"HA Makhlouf","year":"2025","unstructured":"Makhlouf HA, Hassan AK, Almosilhy NA, Osman ASA, Ramadan S, Abouelmagd ME. Exploring the association between statins use or HMG-CoA reductase inhibition and migraine: a systematic review and meta-analysis. J Headache Pain. 2025;26:23. https:\/\/doi.org\/10.1186\/s10194-025-01957-w.","journal-title":"J Headache Pain"},{"key":"4904_CR41","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.jjcc.2013.01.010","volume":"61","author":"T Takayama","year":"2013","unstructured":"Takayama T, Hiro T, Ueda Y, Honye J, Komatsu S, Yamaguchi O, et al. Plaque stabilization by intensive LDL-cholesterol lowering therapy with atorvastatin is delayed in type 2 diabetic patients with coronary artery disease\u2014Serial angioscopic and intravascular ultrasound analysis. J Cardiol. 2013;61:381\u20136. https:\/\/doi.org\/10.1016\/j.jjcc.2013.01.010.","journal-title":"J Cardiol"},{"key":"4904_CR42","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s12016-020-08791-9","volume":"60","author":"K Koushki","year":"2021","unstructured":"Koushki K, Shahbaz SK, Mashayekhi K, Sadeghi M, Zayeri ZD, Taba MY, et al. Anti-inflammatory action of statins in cardiovascular disease: the role of inflammasome and toll-like receptor pathways. Clin Rev Allergy Immunol. 2021;60:175\u201399. https:\/\/doi.org\/10.1007\/s12016-020-08791-9.","journal-title":"Clin Rev Allergy Immunol"},{"key":"4904_CR43","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/6661847","volume":"2021","author":"A Nenna","year":"2021","unstructured":"Nenna A, Nappi F, Lusini M, Satriano UM, Schilir\u00f2 D, Spadaccio C, et al. Effect of statins on platelet activation and function: from molecular pathways to clinical effects. Biomed Res Int. 2021;2021:6661847. https:\/\/doi.org\/10.1155\/2021\/6661847.","journal-title":"Biomed Res Int"},{"key":"4904_CR44","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/4936924","volume":"2017","author":"J Li","year":"2017","unstructured":"Li J, Paulus YM, Shuai Y, Fang W, Liu Q, Yuan S. New developments in the classification, pathogenesis, risk factors, natural history, and treatment of branch retinal vein occlusion. J Ophthalmol. 2017;2017:4936924. https:\/\/doi.org\/10.1155\/2017\/4936924.","journal-title":"J Ophthalmol"},{"key":"4904_CR45","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12933-016-0408-3","volume":"15","author":"JW Yu","year":"2016","unstructured":"Yu JW, Deng YP, Han X, Ren GF, Cai J, Jiang GJ. Metformin improves the angiogenic functions of endothelial progenitor cells via activating AMPK\/eNOS pathway in diabetic mice. Cardiovasc Diabetol. 2016;15:88 https:\/\/doi.org\/10.1186\/s12933-016-0408-3.","journal-title":"Cardiovasc Diabetol"},{"key":"4904_CR46","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1547492","volume":"16","author":"X Wang","year":"2025","unstructured":"Wang X, Liang X, Huang S, Wei M, Xu Y, Chen X, et al. Metformin inhibits pathological retinal neovascularization but promotes retinal fibrosis in experimental neovascular age-related macular degeneration. Front Pharm. 2025;16:1547492. https:\/\/doi.org\/10.3389\/fphar.2025.1547492.","journal-title":"Front Pharm"},{"key":"4904_CR47","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1177\/15353702211069986","volume":"247","author":"SV Amin","year":"2022","unstructured":"Amin SV, Khanna S, Parvar SP, Shaw LT, Dao D, Hariprasad SM, et al. Metformin and retinal diseases in preclinical and clinical studies: Insights and review of literature. Exp Biol Med (Maywood). 2022;247:317\u201329. https:\/\/doi.org\/10.1177\/15353702211069986.","journal-title":"Exp Biol Med (Maywood)"},{"key":"4904_CR48","doi-asserted-by":"publisher","first-page":"2464","DOI":"10.3390\/healthcare12232464","volume":"12","author":"R Brata","year":"2024","unstructured":"Brata R, Pascalau AV, Fratila O, Paul I, Muresan MM, Camarasan A, et al. Hemodynamic effects of SGLT2 inhibitors in patients with and without diabetes mellitus-a narrative review. Healthc (Basel). 2024;12:2464 https:\/\/doi.org\/10.3390\/healthcare12232464.","journal-title":"Healthc (Basel)"},{"key":"4904_CR49","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3390\/metabo11020087","volume":"11","author":"Z Szekeres","year":"2021","unstructured":"Szekeres Z, Toth K, Szabados E. The effects of SGLT2 inhibitors on lipid metabolism. Metabolites. 2021;11:87 https:\/\/doi.org\/10.3390\/metabo11020087.","journal-title":"Metabolites"},{"key":"4904_CR50","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1161\/ATVBAHA.115.305447","volume":"35","author":"MM Smits","year":"2015","unstructured":"Smits MM, Muskiet MHA, Tonneijck L, Kramer MHH, Diamant M, Van Raalte DH, et al. GLP-1 receptor agonist exenatide increases capillary perfusion independent of nitric oxide in healthy overweight men. ATVB. 2015;35:1538\u201343. https:\/\/doi.org\/10.1161\/ATVBAHA.115.305447.","journal-title":"ATVB"},{"key":"4904_CR51","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1001\/jamainternmed.2022.6664","volume":"183","author":"E D\u2019Andrea","year":"2023","unstructured":"D\u2019Andrea E, Wexler DJ, Kim SC, Paik JM, Alt E, Patorno E. Comparing effectiveness and safety of SGLT2 inhibitors vs DPP-4 inhibitors in patients with type 2 diabetes and varying baseline HbA1c levels. JAMA Intern Med. 2023;183:242\u201354. https:\/\/doi.org\/10.1001\/jamainternmed.2022.6664.","journal-title":"JAMA Intern Med"},{"key":"4904_CR52","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.pcd.2021.11.006","volume":"16","author":"L Xu","year":"2022","unstructured":"Xu L, Zheng XQ, Liao XX. Cardiovascular effectiveness of glucagon-like peptide 1 receptor agonists versus dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a meta-analysis based on propensity score-matched studies. Prim Care Diab. 2022;16:207\u201310. https:\/\/doi.org\/10.1016\/j.pcd.2021.11.006.","journal-title":"Prim Care Diab"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04904-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04904-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04904-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T16:08:47Z","timestamp":1794413327000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04904-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,24]]},"references-count":52,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["4904"],"URL":"https:\/\/doi.org\/10.1038\/s41433-026-04904-4","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,24]]},"assertion":[{"value":"20 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Anas Alamoudi: None. Ahmed Alnabihi: None. Sultan Al-Qahtani: None. Waleed K. Alsarhani: None. Peter J Kertes: Honoraria: Amgen, Novartis, Bayer, Roche, Boehringer Ingelheim, RegenxBio, Apellis, Astellas. Advisory board\u2014Novartis, Johnson and Johnson, Kriya Therapeutics, Amgen, Novartis, Bayer, Roche, RegenxBio, Apellis, Astellas. Financial support (to institution)\u2014Apotex, Roche, Novartis, Bayer, RegenxBio, Johnson and Johnson, Neuracle Genetics.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}]}}